Market Overview

Altria's Reported Interest In Juul Wins Sell-Side Support

Share:
Altria's Reported Interest In Juul Wins Sell-Side Support

Marlboro producer Altria Group Inc (NYSE: MO) is in talks to buy a large minority stake in leading e-cigarette start-up Juul Labs, according to a Wednesday Wall Street Journal report.

Why It’s Important

Experts lauded Altria’s diversification effort given the increasingly fragmented market.

“Strategically, a stake in Juul could make sense for Altria, as it would give it exposure to a fast growing product that poses a threat to its cigarette business,” according to Morgan Stanley. “Altria does not have a robust reduced-risk product portfolio, and Juul's brand leadership and first-mover advantage in cartridge-based nicotine salt e-cigs could significantly enhance Altria's competitive position.”

By Bank of America Merrill Lynch’s estimates, Altria could conquer the vape category via Juul’s expanding 62-percent share while also recapturing competitive losses.

“Juul has had a stellar run in the latest 52-week period, with sales up 962-percent year-over-year,” according to BofA. “Juul's outperformance has been a drag on Altria’s stock price since at least the beginning of 2018, as its vapor share gains accelerated and investors fretted over Juul's performance [and] impact on combustibles.”

Ultimately, Juul could help Altria expand not only market share, but market power.

“Altria could potentially be able to better preserve the U.S. cigarette profit pool through an ownership interest in Juul by having greater influence over reduced risk pricing dynamics,” Morgan Stanley said, noting that Juul pods sell at a 30-percent discount to cigarettes.

Altria faces risk in increasingly unfavorable e-cigarette regulations, particularly amid heightened concerns over the product’s teen appeal.

The Deal's Feasability 

Juul was valued at $16 billion this summer and recorded $1.8 billion in retail sales last year — making it one of the nation’s most valuable start-ups. Yet Morgan Stanley suspects recent FDA crackdowns could depress the current value, and said Altria’s underlevered balance sheet could help.

BofA said: “Altria's current leverage is conservative ... suggesting to us that Altria could boost debt by $16 billion and still stay in compliance with their credit agreement covenants." 

What’s Next

Neither Altria nor Juul have confirmed the reported talks, but Altria has a history of investing in cigarette alternatives, including smokeless tobacco products and cigars.

The WSJ said a deal is weeks away — if it is to happen at all.

Related Links:

Analysts Weigh In On The FDA's Position On E-Cigarettes, Menthols

How The FDA May Be Overstepping Bounds With New E-Cigarette Policy

Latest Ratings for MO

DateFirmActionFromTo
Aug 2019MaintainsUnderweight
Jul 2019MaintainsUnderweight
Jul 2019UpgradesNeutralBuy

View More Analyst Ratings for MO
View the Latest Analyst Ratings

Posted-In: E-Cigarettes JUUL VapingAnalyst Color M&A News Analyst Ratings Media Best of Benzinga

 

Related Articles (MO)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
XELMaintains60.0
SOMaintains54.0
SREMaintains141.0
EXCMaintains56.0
ESMaintains77.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Twitter's Stock Falls And Nobody Really Knows Why

Canopy Growth, MediPharm Labs Enter Cannabis Supply Agreement